SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Cabergoline Tablets (Greenstone LLC)

Trade Name: Not applicable
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for lactation inhibition

Details of the Supplier of the Safety Data Sheet

Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Other Hazards No data available
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Cabergoline	81409-90-7	Not Listed	Xn;R22	Acute Tox.4 (H302)	1.25

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Leucine	61-90-5	200-522-0	Not Listed	Not Listed	*
Lactose NF, anhydrous	63-42-3	200-559-2	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Restrict access to work area. Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. It is recommended that all operations be fully enclosed and no air recirculated. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Leucine

Latvia OEL - TWA 5 mg/m^3

Manufacturer OEB Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Cabergoline
Manufacturer OEB: OEB5 (control exposure to <1ug/m^3)

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes: Wear safety glasses or goggles if eye contact is possible.
Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	**Color:**	White
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Cabergoline
No data available
Leucine
No data available
Lactose NF, anhydrous
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions

Oxidizing Properties:	No data available
Conditions to Avoid:	None known
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Short Term: Active ingredient may be harmful if swallowed. (based on animal data) Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. This drug may decrease the quantity/quality of breast milk.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Cabergoline
Rat Oral LD 50 383 (F) mg/kg
Rat Para-periosteal LD 50 22mg/kg
Mouse Oral LD 50 202 (F)mg/kg
Mouse Intravenous LD 50 24 (F)mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Cabergoline
Skin Sensitization - GPMT Guinea Pig No effect

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Cabergoline
Embryo / Fetal Development Rat Oral0.012 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 8 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Mouse Oral 8 mg/kg/day Not Teratogenic, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cabergoline
In Vitro Mammalian Cell Mutagenicity Hamster Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vitro Micronucleus Mouse Bone Marrow Negative
In Vitro Direct DNA Damage Bacteria Negative
Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cabergoline
24 Month(s) Rat Oral 0.320 mg/kg/day Not carcinogenic
21 Month(s) Mouse Oral 0.980 mg/kg/day Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Cabergoline

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Leucine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-522-0

Lactose NF, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Xn - Harmful

R22 - Harmful if swallowed.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information.

Revision date: 14-Jul-2014

Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet